Patient Recruitment · 2026
Clinical Trial Recruitment Source Attribution
Ask which channel is driving enquiries on a study and most teams answer easily. Ask which of those channels is actually producing enrolled patients, and the confidence drops sharply — that gap is where most recruitment spend becomes a guess.
Panacea Patient Recruitment · Patient recruitment specialists for clinical trials · Last updated: 29 August 2026
Patient Recruitment · 2026
Recruitment Source
Attribution
Knowing where enquiries came from isn’t the same as knowing what worked
Clinical trial recruitment source attribution is what tells you whether a channel actually produced an enrolled patient — not just whether it produced an enquiry, which is the part almost every recruitment dashboard already shows.
Key Takeaways
- Sourcing gets tracked because it’s easy to count. Attribution — following a patient from the channel that found them through to the outcome at the end — is harder, and it’s the part that actually tells you whether the spend was worth it.
- A channel can generate a large number of enquiries and still be a weak source of enrolled patients if those enquiries convert poorly at pre-screening — a blind spot covered from a different angle in the hidden cost of a good-enough recruitment percentage.
- Attribution is a four-link chain — captured at enquiry, carried through transfer, recorded against outcome, reported upstream — and breaking any single link breaks the whole thing.
- A 2025 case study of a real clinical trial referral service found enquiry volume grew from 229 in 2018 to 1,747 by 2020 — while its own authors disclose it never tracked whether those enquiries reached a study team or resulted in enrolment (Chatterjee et al., 2025).
- In general healthcare referral loops, almost 70% of specialists received no information from the referring provider before seeing a patient, and 25% of primary care physicians never received outcome information back within four weeks (Gandhi et al., 2000, via IHI/NPSF).
- In a 2021 survey of over 200 businesses, 42% reported using no attribution tool at all to measure their marketing — tracking activity and proving what worked are two different things.
- Without attribution, budget defaults to whatever the last plan said or whichever channel feels busiest — turning outcome data into a decision is what actually closes the loop.
What is clinical trial recruitment source attribution, and why isn’t sourcing enough on its own?
Ask which channel is driving enquiries on a given study, and most teams can answer the first half of that question easily — where enquiries are coming from. Ask which of those channels is actually producing enrolled patients, and the confidence usually drops sharply. Sourcing gets tracked because it’s easy to count. Attribution — following a patient from the channel that found them through to the outcome at the end — is harder, and it’s the part that actually tells you whether the spend was worth it.
This is the gap between activity and evidence. A dashboard full of enquiry counts by channel looks like recruitment intelligence. Without attribution through to enrolment, it’s really just a record of where interest came from — not where results came from, a distinction that matters as much for choosing a channel mix as for judging one already in place.
Why doesn’t enquiry volume tell you whether a recruitment source is working?
A channel can generate a large number of enquiries and still be a weak source of enrolled patients, if those enquiries convert poorly once they reach pre-screening. Conversely, a smaller, quieter channel can be quietly outperforming a louder one on the metric that actually matters. Without attribution connecting source to eventual outcome, there’s no way to tell these two situations apart — they look identical on an enquiry-volume report.
This is what makes a dominant source without attribution a genuine visibility gap, not a strength. If most of a study’s patients are coming through one channel and nobody can trace what happens to them after that point, the study doesn’t actually know whether that channel is working. It knows the channel is busy, which isn’t the same thing.
What does attribution actually require?
Attribution isn’t a single feature — it’s a chain that has to hold together end to end. The source has to be captured at the point of enquiry, not inferred later. The referral has to carry that source information through transfer, so it isn’t lost when it moves to whoever acts on it — the same handoff point examined from a tooling angle in CRM vs spreadsheet for referral tracking. The outcome has to be recorded against that same reference. And that outcome data has to be reported back to the people who control spend, not just filed away in a site-level system nobody upstream ever sees.
Capture at enquiry
Survive transfer
Outcome recorded
Reported upstream
Red marks the link that breaks most often: a study can capture source perfectly at enquiry and still have no usable attribution if outcomes never make it back upstream.
What is the closed-loop problem in recruitment attribution?
The most expensive version of this gap isn’t just not knowing which channel worked. It’s continuing to spend as though the question had already been answered. Without attribution, budget allocation defaults to whatever the last plan said, or whatever channel feels most active, rather than what the data shows is actually converting. A study can spend a full recruitment cycle reinforcing a channel that looks productive by volume and quietly underperforms by outcome.
Recording an outcome is a data-entry task. Using it to adjust which channels get more attention, more budget, or less, mid-study, is what turns tracking into actual recruitment intelligence — the same distinction covered end to end in closing the loop in clinical trial recruitment.
What does the evidence say about how often this chain breaks?
The clearest documented example is a clinical trial referral service itself. Duke University’s My Research Partners concierge service tracked its own enquiry volume in detail — 229 queries in 2018, 590 in 2019, and 1,747 interactions in 2020 — but its own published evaluation explicitly states the service never tracked how many callers actually reached a study team member or ended up enrolling. Source capture worked. The chain still produced no usable attribution, because nobody closed the last link.
General healthcare referral research shows the same pattern. One widely cited study found that almost 70% of specialists received no information from the referring provider prior to seeing a patient, and 25% of primary care practitioners failed to receive information back within four weeks. A separate review found only about half of specialist referrals were completed end to end. And in a 2021 survey of over 200 businesses, 42% reported using no attribution tool at all.
| Link in the chain | What has to happen | What commonly breaks it |
|---|---|---|
| 1. Capture at enquiry | Source recorded reliably, for every channel — not just the loudest one | Quieter channels go unrecorded while the dominant one gets logged by default |
| 2. Survive transfer | Source data moves with the referral as it is actioned | Lost in the handoff between systems |
| 3. Outcome recorded | Enrolment, screen failure, or dropout traced back to its source | Outcome logged at site level, never linked to the originating channel |
| 4. Reported upstream | Traced data reaches whoever actually controls spend | Stops at site level — 70% of specialists got no referrer context, 25% of PCPs nothing back |
Why do CMOs and project managers both need attribution, for different reasons?
For a project manager, attribution answers an operational question: which channel is worth doubling down on right now, given what’s actually converting — the same forward-looking judgment behind setting the right recruitment benchmark in the first place. For a chief medical officer or sponsor-facing lead, it answers a governance question: can the recruitment spend on this study be justified with evidence, or does it rest on assumption. Both depend on the same chain — they just use the answer differently.
What does this mean for diversity and equity commitments?
A study can report that it used a broad, inclusive set of sourcing channels without being able to show that those channels actually produced enrolled, diverse patients. Attribution is what turns a channel list into evidence that the sourcing strategy worked as intended, rather than a list of good intentions.
How do you check whether attribution is working on your own study?
If attribution is uncertain on a given study, the fastest place to look isn’t the reporting dashboard — it’s the chain itself.
- Is source captured at the point of enquiry, reliably, for every channel — not just the largest one?
- Does that source information survive the handover from wherever it is captured to wherever referrals are actioned?
- Can an eventual enrolment — or a screen failure, or a dropout — be traced back to its originating source?
- Does anyone with control over recruitment spend actually see that traced-back data, or does it stop at site level?
- When that data does surface, does it change anything — or does the next cycle's spend look the same regardless?
A gap at any of these points is worth finding before assuming the recruitment strategy itself is the problem. Often it isn’t the sourcing that needs to change — it’s the visibility into what the sourcing already produced, the same reframing at the heart of why is your clinical trial under-enrolling.
Find out whether your recruitment spend can actually be traced
A structured recruitment diagnostic looks specifically at whether this chain holds together across a study’s own pathway, not just whether outcomes are recorded somewhere.
Take the Recruitment DiagnosticMethodology & sourcing note
The clinical-trial-specific anchor for this article is Chatterjee et al.’s February 2025 description of Duke University’s My Research Partners concierge referral service, published in the Journal of Clinical and Translational Science, which documents rising enquiry volume alongside an explicit admission that enrolment outcomes were never tracked. The general-healthcare referral-loop statistics (Gandhi et al., 2000; Weiner et al., 2010) are drawn from an Institute for Healthcare Improvement / National Patient Safety Foundation guide and are used as analogous evidence for the same chain-breaking mechanism, not as clinical-trial figures. The marketing-attribution statistic comes from Ruler Analytics’ 2021 survey of over 200 businesses and is disclosed here as general marketing-industry research.
Frequently asked questions
Panacea Patient Recruitment
Patient recruitment specialists for clinical trials · panaceapatientrecruitment.com/about-us
Last updated: 29 August 2026